Kilitch Drugs (India) Ltd (KILITCH) — shareholding pattern, promoter holding, financials and share price
About Kilitch Drugs (India) Ltd (KILITCH)
Kilitch Drugs (India) Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as KILITCH and on the BSE under scrip code 524500. Its ISIN is INE729D01010.
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products [1]
Kilitch Drugs (India) Limited (KDIL) is a leading pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations in various dosage forms across the globe.
KDIL has a strong presence in injectables and is one of the largest manufacturers of cephalosporins in Africa, with manufacturing units in India and Ethiopia.
Listed peers in Pharmaceuticals: Anuh Pharma Ltd, Amanta Healthcare Ltd, Influx Healthtech Ltd, Zim Laboratories Ltd, Haleos Labs Limited, Jenburkt Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹185 a share on 10 Jul 2026, Kilitch Drugs (India) Ltd (KILITCH) was valued at a price-to-earnings ratio of 21.93x against an industry P/E of 36.41x and a price-to-book of 3.2x on a book value of ₹57.87 per share as of Mar 2025. Solomo computes return on equity of 14.58% and return on capital employed of 17.56% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 21.93x
- Industry P/E
- 36.41x
- P/B
- 3.2x
- EPS (TTM)
- ₹8.44
- Book value / share
- ₹57.87
- ROE
- 14.58%
- ROCE
- 17.56%
- ROA
- 9.43%
- Debt / equity
- 0.24x
- Dividend yield
- 0%
- EBITDA margin
- 20.32%
- 52-week range
- ₹121.1 – ₹245
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Kilitch Drugs (India) Ltd (KILITCH) reported revenue of ₹235 crore, net profit of ₹30 crore and earnings per share of ₹8.63. That compares with revenue of ₹198 crore and net profit of ₹25 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹90 crore and net profit ₹15 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 114 | 140 | 154 | 198 | 235 |
| Net profit (₹ cr) | 6 | 8 | 14 | 25 | 30 |
| EPS (₹) | 2.17 | 3.08 | 4.17 | 7.63 | 8.63 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 27.07% | 24.47% | 19.97% | 28.47% |
| Profit growth | - | 47.54% | 43.57% | 83.65% |
| Stock price CAGR | 27% | 18% | 26% | -20% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.77% of Kilitch Drugs (India) Ltd (KILITCH) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.12% and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹647 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Dipak Kanayalal Shah 3.2%, Investor Education and Protection Fund Authority 2.29%, HUF 1.56%, Mukul Mahavir Agrawal 1.34%, Premilaben Rameshchandra Shah 1.14%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.77% | - | 0.12% | 0% | 36.23% |
| Mar 2026 | 63.77% | - | 0% | 0% | 36.23% |
| Dec 2025 | 63.77% | - | 0% | 0% | 36.23% |
| Sep 2025 | 63.77% | - | 0% | 0% | 36.23% |
| Jun 2025 | 69.23% | - | 0% | 0% | 30.77% |
| Mar 2025 | 69.23% | - | - | 0% | 30.77% |
| Dec 2024 | 69.23% | - | 0% | 0% | 30.77% |
| Sep 2024 | 69.23% | - | 0% | 0% | 30.77% |